- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer | 71 | GlobeNewswire (Europe) | Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line triple-negative breast cancer (TNBC)Initiation... ► Artikel lesen | |
| Mo | IMMUNEONCO-B (01541): INSIDE INFORMATION - UPDATE ON GLOBAL REGISTRATIONAL STRATEGY FOR IMM2510 FOR NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST ... | 1 | HKEx | ||
| Fr | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - TRANSFER OF EQUITY INTEREST IN A SUBSIDIARY | - | HKEx | ||
| 11.09. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M | 1 | HKEx | ||
| 10.09. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS | 2 | HKEx | ||
| 04.09. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 04.09. | IMMUNEONCO-B (01541): INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
| 03.09. | IMMUNEONCO-B (01541): INSIDE INFORMATION - THE H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE | 1 | HKEx | ||
| 26.08. | IMMUNEONCO-B (01541): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
| 22.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPFRONT PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M | - | HKEx | ||
| 14.08. | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | - | HKEx | ||
| 14.08. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 14.08.2024 | 332 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.08.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.08.2024
Aktien
1 CNE100006624 Immuneonco Biopharmaceuticals... ► Artikel lesen | |
| 01.08. | Instil Bio to in-license cancer candidates from ImmuneOnco | 2 | Seeking Alpha | ||
| 01.08. | IMMUNEONCO-B (01541): INSIDE INFORMATION - LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M | 1 | HKEx | ||
| 01.08. | Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody | 192 | GlobeNewswire (Europe) | DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, "ImmuneOnco"), today announced... ► Artikel lesen | |
| 30.07. | IMMUNEONCO-B (01541): (1) RESIGNATION OF SUPERVISOR; AND (2) ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR | 2 | HKEx | ||
| 24.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M | - | HKEx | ||
| 03.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH TISLELIZUMAB | - | HKEx | ||
| 21.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMC-002 | 1 | HKEx | ||
| 03.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE ... | 1 | HKEx |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PORTAGE BIOTECH | 9,850 | 0,00 % | Pre-market Movers: Portage Biotech, Veea, Intuitive Machines, Applied Therapeutics, Galmed Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Portage Biotech Inc. (PRTG) is up over 179% at... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,550 | 0,00 % | ROUNDUP/Aktien New York: Neue Rekorde vor US-Zinsentscheid | NEW YORK (dpa-AFX) - Vor dem Zinsentscheid der US-Notenbank Fed bleiben die Anleger an den New Yorker Börsen optimistisch. Der Leitindex Dow Jones Industrial markierte am Dienstag gleich zu Beginn... ► Artikel lesen | |
| BIONTECH | 105,30 | +1,15 % | Aktien New York Ausblick: Weitere moderate Gewinne | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Donnerstag auf weitere moderate Gewinne zu. Erzeugerpreise und die wöchentlichen Erstanträge auf Arbeitslosenhilfe konnten die Stimmung nur wenig trüben.... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,300 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Set to Join S&P SmallCap 600 Index | RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,620 | 0,00 % | Unveiling 7 Analyst Insights On Avidity Biosciences | ||
| QIAGEN | 41,490 | +0,73 % | Biotech Report: Biontech ziehen an, Qiagen erneut leichter | (shareribs.com) Frankfurt / New York 12.09.2024 - Biotech-Aktien tendierten im deutschen Handel überwiegend schwächer. Biontech und 4SC konnten zulegen. An der Wall Street konnte der Sektor derweil... ► Artikel lesen | |
| EVOTEC | 6,570 | +1,70 % | Evotec Aktie: Gelingt eine Überraschung wie bei HelloFresh? | Es könnte spannend werden bei der Evotec Aktie, bei der zuletzt einige "Insiderkäufe" zu sehen waren, zugleich Shortseller sehr aktiv sind. In einer ähnlichen Konstellation sorgte gestern bei HelloFresh... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 53,21 | 0,00 % | Moonlake Immunotherapeutics behält Buy-Bewertung aufgrund von HS- und PsA-Potenzial | ||
| EDGEWISE THERAPEUTICS | 19,040 | 0,00 % | Edgewise rises after early trial results for heart disease therapy | ||
| NUVALENT | 102,76 | 0,00 % | Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally? | ||
| ARRIVENT BIOPHARMA | 23,580 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2024 Financial Results | Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,900 | 0,00 % | Angle PLC Announces Agreement with Recursion Pharmaceuticals | New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating... ► Artikel lesen | |
| ARCELLX | 80,55 | 0,00 % | ACLX, HROW Deliver Triple-Digit Returns - Did You Cash In? | WASHINGTON (dpa-AFX) - Many traders seek instant gratification in the stock market. Some stocks offer quick profits, while others require a patient, long-term approach for significant returns.... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 29,310 | 0,00 % | Baird maintains Outperform rating on Longboard Pharmaceuticals stock with steady price target | ||
| IMMUNOVANT | 28,990 | 0,00 % | Immunovant stock maintains Overweight rating from Piper Sandler |
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,581 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.
